A Phase I Study of Intravenously Administered FAU (1-(2'-Deoxy-2'-Fluoro-beta-D-Arabinofuranosyl) Uracil, NSC 678515) in Patients With Advanced Solid Tumors.

Trial Profile

A Phase I Study of Intravenously Administered FAU (1-(2'-Deoxy-2'-Fluoro-beta-D-Arabinofuranosyl) Uracil, NSC 678515) in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs NSC 678515 (Primary)
  • Indications Hodgkin's disease; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Apr 2016 Results assessing conventional plasma pharmacokinetic evaluation of therapeutic FAU and dynamic PET assessment of 18 F-FAU published in the Journal of Clinical Pharmacology.
    • 02 May 2013 Planned End Date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 02 May 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top